SG11201400405TA - Caninised antibodies and method for the production of same - Google Patents

Caninised antibodies and method for the production of same

Info

Publication number
SG11201400405TA
SG11201400405TA SG11201400405TA SG11201400405TA SG11201400405TA SG 11201400405T A SG11201400405T A SG 11201400405TA SG 11201400405T A SG11201400405T A SG 11201400405TA SG 11201400405T A SG11201400405T A SG 11201400405TA SG 11201400405T A SG11201400405T A SG 11201400405TA
Authority
SG
Singapore
Prior art keywords
production
same
caninised antibodies
caninised
antibodies
Prior art date
Application number
SG11201400405TA
Other languages
English (en)
Inventor
David Gearing
Original Assignee
Nvip Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nvip Pty Ltd filed Critical Nvip Pty Ltd
Publication of SG11201400405TA publication Critical patent/SG11201400405TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/48Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG11201400405TA 2011-09-06 2012-09-05 Caninised antibodies and method for the production of same SG11201400405TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531439P 2011-09-06 2011-09-06
PCT/GB2012/052174 WO2013034900A1 (en) 2011-09-06 2012-09-05 Caninised antibodies and method for the production of same

Publications (1)

Publication Number Publication Date
SG11201400405TA true SG11201400405TA (en) 2014-04-28

Family

ID=46881091

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400405TA SG11201400405TA (en) 2011-09-06 2012-09-05 Caninised antibodies and method for the production of same

Country Status (11)

Country Link
US (1) US20140328838A1 (zh)
EP (1) EP2753645B1 (zh)
JP (5) JP6010127B2 (zh)
KR (2) KR20140062127A (zh)
CN (1) CN103906764A (zh)
AU (1) AU2012306067B9 (zh)
CA (2) CA2835094C (zh)
ES (1) ES2665016T3 (zh)
SG (1) SG11201400405TA (zh)
TW (1) TW201326206A (zh)
WO (1) WO2013034900A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
WO2016050721A1 (en) 2014-09-30 2016-04-07 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
MX2020001707A (es) * 2017-08-15 2020-03-20 Kindred Biosciences Inc Variantes igg fc para uso veterinario.
BR112020017701A2 (pt) * 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
EP4114856A4 (en) * 2020-03-03 2023-11-22 Scout Bio, Inc. ANTIGEN BINDING MOLECULES AND USES THEREOF
CN117153253B (zh) * 2022-09-09 2024-05-07 南京金斯瑞生物科技有限公司 一种设计人源化抗体序列的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
CA2469833C (en) * 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20040212A1 (it) * 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US8337842B2 (en) * 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
AU2011291462A1 (en) * 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same

Also Published As

Publication number Publication date
JP6010127B2 (ja) 2016-10-19
AU2012306067B2 (en) 2017-01-19
JP2016040322A (ja) 2016-03-24
JP2019089772A (ja) 2019-06-13
KR20140062127A (ko) 2014-05-22
JP2016171812A (ja) 2016-09-29
AU2012306067B9 (en) 2017-02-23
NZ622326A (en) 2015-10-30
JP2017110015A (ja) 2017-06-22
CA2835094C (en) 2020-12-22
JP2014527806A (ja) 2014-10-23
CA2835094A1 (en) 2012-11-15
EP2753645A1 (en) 2014-07-16
WO2013034900A1 (en) 2013-03-14
KR20190094253A (ko) 2019-08-12
AU2012306067A1 (en) 2014-03-20
EP2753645B1 (en) 2018-02-21
CN103906764A (zh) 2014-07-02
US20140328838A1 (en) 2014-11-06
CA2847824A1 (en) 2013-03-14
TW201326206A (zh) 2013-07-01
ES2665016T3 (es) 2018-04-24

Similar Documents

Publication Publication Date Title
GB201223276D0 (en) Antibodies and methods of producing same
HK1199882A1 (zh) 用於製備雌四醇的方法
ZA201305972B (en) Method for the preparation of biphephos
HRP20181747T1 (hr) Postupak za selektivnu proizvodnju n-metil-para-anisidina
EP2722540A4 (en) STABILIZATION COMPOUND AND METHOD OF MANUFACTURING THEREOF
EP2716952A4 (en) CONNECTION, AND METHOD OF MANUFACTURING THE SAME
EP2774982A4 (en) PROCESS FOR SECRETION AND PRODUCTION OF PROTEINS
SG11201400405TA (en) Caninised antibodies and method for the production of same
EP2915819A4 (en) METHOD FOR PRODUCING ANTIBODIES AND ANTIBODY COMPOSITION
EP2709127A4 (en) BELLOWS AND METHOD OF MANUFACTURING THE SAME
SG10201604976RA (en) Hydroxy-aminopolymers and method for producing same
GB201207599D0 (en) Transistor and the method of manufacture
PL2686462T5 (pl) Ciało powlekane i sposób jego wytwarzania
IL228073A0 (en) Method for the determination of polysorbate
EP2698159A4 (en) PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF
GB201302649D0 (en) A method of increasing the effect of an activated-potentiated form of an antibody
GB2493451B (en) Super-hard construction and method for making same
SG11201401251TA (en) Slurry and method for producing slurry
EP2737065A4 (en) PROCESS FOR PRODUCING PROTEINS
GB2487128B (en) Carton and method of assembly thereof
EP2752416A4 (en) NOVEL MANGROMICIN COMPOUND AND PROCESS FOR PRODUCING THE SAME
EP2695938A4 (en) METHOD FOR PRODUCING ANTIBODIES
EP2772544A4 (en) NEW CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
GB201106570D0 (en) Methods and apparatus for the production of metal
IL219621A (en) Diaper and method of manufacture